Lenka Bešše

821 total citations
39 papers, 399 citations indexed

About

Lenka Bešše is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Lenka Bešše has authored 39 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 28 papers in Hematology and 9 papers in Oncology. Recurrent topics in Lenka Bešše's work include Multiple Myeloma Research and Treatments (26 papers), Ubiquitin and proteasome pathways (17 papers) and Protein Degradation and Inhibitors (10 papers). Lenka Bešše is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Ubiquitin and proteasome pathways (17 papers) and Protein Degradation and Inhibitors (10 papers). Lenka Bešše collaborates with scholars based in Switzerland, Czechia and Netherlands. Lenka Bešše's co-authors include Christoph Driessen, Andrej Bešše, Marianne Kraus, Lenka Sedlaříková, Sabina Ševčı́ková, Herman S. Overkleeft, Elmer Maurits, Roman Hájek, Jürgen Bader and Gerjan de Bruin and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Lenka Bešše

36 papers receiving 394 citations

Peers

Countries citing papers authored by Lenka Bešše

Since Specialization

Citations

This map shows the geographic impact of Lenka Bešše's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lenka Bešše with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lenka Bešše more than expected).

Fields of papers citing papers by Lenka Bešše

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lenka Bešše. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lenka Bešše. The network helps show where Lenka Bešše may publish in the future.

Co-authorship network of co-authors of Lenka Bešše

This figure shows the co-authorship network connecting the top 25 collaborators of Lenka Bešše. A scholar is included among the top collaborators of Lenka Bešše based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lenka Bešše. Lenka Bešše is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting proteostasis in multiple myeloma through inhibition of LTK 2025 ·Leukemia ·Thea Kristin Våtsveen, (unknown), (unknown), (unknown), Andrej Bešše, (unknown), Sigrid S. Skånland, Anders Tveita, (unknown), (unknown), Kristine Misund, Veronika Reiterer, (unknown), Christoph Driessen, Lenka Bešše, Kjetil Taskén, Fredrik Schjesvold, Hesso Farhan, Ludvig A. Munthe	1
2	Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system 2025 ·iScience ·(unknown), Andrej Bešše, Christian Zuppinger, Christian Perez‐Shibayama, Cristina Gil‐Cruz, Bogdan I. Florea, Angelina De Martin, Mechthild Lütge, (unknown), (unknown), Xiang Zhou, Leo Rasche, Jan Přibyl, Vladimír Rotrekl, Burkhard Ludewig, Herman S. Overkleeft, Lenka Bešše, Christoph Driessen	0
3	Abstract 2974: Bortezomib resistant multiple myeloma shows a specific dependency on Ecm29 in vitro and in vivo 2025 ·Cancer Research ·Andrej Bešše, Lenka Bešše, Sara Christina Stolze, Marianne Kraus, Ondřej Slabý, Hirofumi Nakagami, Christoph Driessen	0
4	HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer 2024 ·British Journal of Cancer ·(unknown), Lenka Sedlaříková, (unknown), Marianne Kraus, (unknown), Nicol Straková, Karel Souček, Jiří Navrátil, (unknown), Alana L. Welm, Markus Joerger, Christoph Driessen, Lenka Bešše	2
5	The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma 2023 ·Scientific Reports ·Lenka Bešše, Marianne Kraus, Andrej Bešše, Christoph Driessen, Ignazio Tarantino	5
6	Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma 2023 ·Blood ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tobias Schulze, Piero Giansanti, Lenka Bešše, Christoph Driessen, Angela M. Krackhardt, Bernhard Küster, Florian Bassermann	3
7	Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma 2023 ·Blood ·(unknown), Andrej Bešše, (unknown), Marianne Kraus, (unknown), Marija Buljan, Mario van der Stelt, Lenka Bešše, Christoph Driessen	1
8	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors 2022 ·Frontiers in Oncology ·(unknown), Andrej Bešše, Christoph Driessen, Lenka Bešše	11
9	Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors 2022 ·Cells ·Andrej Bešše, Marianne Kraus, (unknown), Elmer Maurits, Herman S. Overkleeft, Christoph Driessen, Lenka Bešše	4
10	Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis 2019 ·Life Science Alliance ·(unknown), Oltin T. Pop, Evangelos Triantafyllou, (unknown), Arjuna Singanayagam, Christian Perez‐Shibayama, Lenka Bešše, Jovana Cupovic, Patrizia Künzler‐Heule, (unknown), Stephan Brand, David Semela, François H.T. Duong, Chris J. Weston, Burkhard Ludewig, Markus H. Heim, Julia Wendon, Charalambos G. Antoniades, Christine Bernsmeier	30
11	Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors 2019 ·Cell chemical biology ·Andrej Bešše, Lenka Bešše, Marianne Kraus, (unknown), Jürgen Bader, Bo‐Tao Xin, Gerjan de Bruin, Elmer Maurits, Herman S. Overkleeft, Christoph Driessen	84
12	Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion 2017 ·Blood ·Andrej Bešše, Lenka Bešše, Sara Christina Stolze, Marianne Kraus, (unknown), Herman S. Overkleeft, Christoph Driessen	1
13	Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus ( HIV )‐protease inhibitors lopinavir or nelfinavir 2017 ·British Journal of Urology ·Dominik Abt, Andrej Bešše, Lenka Sedlaříková, Marianne Kraus, (unknown), Tobias Silzle, (unknown), Ondřej Slabý, Hans‐Peter Schmid, Daniel Engeler, Christoph Driessen, Lenka Bešše	11
14	Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma 2015 ·PLoS ONE ·Lenka Bešše, Lenka Sedlaříková, Fedor Kryukov, Jana Nekvindová, Lenka Radová, Ondřej Slabý, Petr Kuglík, Martina Almáši, Miroslav Penka, Marta Krejčí, Zdeněk Adam, Luděk Pour, Sabina Ševčı́ková, Roman Hájek	18
15	The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells 2015 ·Cancer Chemotherapy and Pharmacology ·(unknown), Marianne Kraus, (unknown), Lenka Bešše, Jürgen Bader, Paul P. Geurink, Gerjan de Bruin, Alexei F. Kisselev, Herman S. Overkleeft, Christoph Driessen	19
16	Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data 2015 ·Biomedical Papers ·Sabina Ševčı́ková, (unknown), Lenka Bešše, Lenka Sedlaříková, (unknown), Martina Almáši, Luděk Pour, Roman Hájek	12
17	Potential of Cell-free Circulating DNA in Diagnosis of Cancer 2015 ·Klinicka onkologie ·(unknown), Lenka Sedlaříková, Lenka Bešše, Martina Almáši, Roman Hájek, Sabina Ševčı́ková	2
18	Cytogenetics in multiple myeloma patients progressing into extramedullary disease 2015 ·European Journal Of Haematology ·Lenka Bešše, Lenka Sedlaříková, Henrieta Grešlíková, (unknown), Martina Almáši, Miroslav Penka, Tomáš Jelı́nek, Luděk Pour, Zdeněk Adam, Petr Kuglík, Marta Krejčí, Roman Hájek, Sabina Ševčı́ková	41
19	Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes 2015 ·Blood ·Lenka Bešše, (unknown), Nan Li, Andrej Bešše, Marianne Kraus, (unknown), Tobias Silzle, Nico J. Meeuwenoord, Hans den Dulk, Herman S. Overkleeft, Bogdan I. Florea, Christoph Driessen	1
20	Degradation of Proteins by Ubiquitin-Proteasome Pathway 2013 ·Klinicka onkologie ·(unknown), Lenka Bešše, Lenka Sedlaříková, (unknown), Roman Hájek, Sabina Ševčı́ková	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact